Tirzepatide vs Semaglutide
| Attribute | Tirzepatide Dual GIP/GLP-1 receptor agonist | Semaglutide GLP-1 receptor agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Dual-agonist weight loss research | Weight loss and blood sugar research |
| In plain English | Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies. | Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down. |
| How it works | Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying. | Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling. |
| Researchers study | Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes. | Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation. |
| Internet discussion | Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules. | The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions. |
Tirzepatide
Dual-agonist weight loss research
Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies.
Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying.
Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes.
Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules.
Tirzepatide is a dual GLP-1/GIP agonist with strong clinical data for weight reduction and glycemic control.
Semaglutide
Weight loss and blood sugar research
Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down.
Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling.
Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation.
The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions.
Semaglutide is the reference GLP-1 agonist — well-studied for blood sugar control and significant weight reduction.